MARKET

AMRN

AMRN

Amarin
NASDAQ
0.8786
-0.0047
-0.53%
After Hours: 0.9638 +0.0852 +9.70% 16:05 04/24 EDT
OPEN
0.8800
PREV CLOSE
0.8833
HIGH
0.8890
LOW
0.8655
VOLUME
656.44K
TURNOVER
0
52 WEEK HIGH
1.485
52 WEEK LOW
0.6510
MARKET CAP
360.82M
P/E (TTM)
-6.0593
1D
5D
1M
3M
1Y
5Y
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Petition filed with the FDA to address significant off-label prescribing of fenofibrates. The filing comes as heart disease continues to be the leading cause of death in the United States. Amarin Corporation plc has no clinical benefit when used in combination with statins to reduce cardiovascular disease risk.
Barchart · 19h ago
Amarin Shareholders Show Strong Support at Annual Meeting
TipRanks · 2d ago
Weekly Report: what happened at AMRN last week (0415-0419)?
Weekly Report · 2d ago
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Home Healthcare Amarin Corporation: Small Signs Of Recovery May Not be Enough. Amarin is going through a turbulent period with a contraction in revenue and margins. The EU and China markets seem too small to make significant changes. The US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin plc is reducing.
Seeking Alpha · 04/16 17:51
Weekly Report: what happened at AMRN last week (0408-0412)?
Weekly Report · 04/15 09:51
Weekly Report: what happened at AMRN last week (0401-0405)?
Weekly Report · 04/08 09:53
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Amarin Corporation plc highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid (EPA) Three data presentations highlight potential effects of EPA on endothelial cell dysfunction and on oxidation of samples enriched with Lp(a)
Barchart · 04/08 07:00
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Barchart · 04/06 14:30
More
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Webull offers Amarin Corporation plc (ADR) stock information, including NASDAQ: AMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMRN stock methods without spending real money on the virtual paper trading platform.